# Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.

> **NCT01762202** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 80 (actual)

## Conditions studied

- B-cell Lymphoid Leukemia
- Young Patients

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT01762202
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-05
- **Primary completion:** 2015-11
- **Final completion:** 2018-10
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01762202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01762202, "Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01762202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*